Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
März, W; Genser, B; Drechsler, C; Krane, V; Grammer, TB; Ritz, E; Stojakovic, T; Scharnagl, H; Winkler, K; Holme, I; Holdaas, H; Wanner, C; German Diabetes and Dialysis Study Investigators.
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
Clin J Am Soc Nephrol. 2011; 6(6):1316-1325
Doi: 10.2215/CJN.09121010
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- März Winfried
- Co-authors Med Uni Graz
- Scharnagl Hubert
- Stojakovic Tatjana
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Patients undergoing maintenance hemodialysis are at high cardiovascular risk. Lowering LDL-cholesterol with statins reduces the incidence rate of cardiovascular events in patients with chronic kidney disease. In contrast, two randomized, prospective, placebo-controlled trials have been completed in hemodialysis patients that showed no significant effects of statins on cardiovascular outcomes. A post hoc analysis was conducted of the 4D (Die Deutsche Diabetes Dialyze) study to investigate whether LDL-cholesterol at baseline is predictive of cardiovascular events and whether the effect of atorvastatin on clinical outcomes depends on LDL-cholesterol at baseline. High concentrations of LDL-cholesterol by tendency increased the risks of cardiac endpoints and all-cause mortality. Concordantly, atorvastatin significantly reduced the rates of adverse outcomes in the highest quartile of LDL-cholesterol (≥145 mg/dl, 3.76 mmol/L). The hazard ratios and 95% confidence intervals were 0.69 (0.48 to 1.00) for the composite primary endpoint, 0.58 (0.34 to 0.99) for cardiac death, 0.48 (0.25 to 0.94) for sudden cardiac death, 0.62 (0.33 to 1.17) for nonfatal myocardial infarction, 0.68 (0.47 to 0.98) for all cardiac events combined, and 0.72 (0.52 to 0.99) for death from all causes, respectively. No such decrease was seen in any of the other quartiles of LDL-cholesterol at baseline. In patients with type 2 diabetes mellitus undergoing hemodialysis, atorvastatin significantly reduces the risk of fatal and nonfatal cardiac events and death from any cause if pretreatment LDL-cholesterol is >145 mg/dl (3.76 mmol/L).
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Atorvastatin -
- Biomarkers - blood
- Cardiovascular Diseases - etiology
- Cardiovascular Diseases - mortality
- Cardiovascular Diseases - prevention & control
- Cholesterol, LDL - blood
- Diabetes Mellitus, Type 2 - blood
- Diabetes Mellitus, Type 2 - complications
- Diabetes Mellitus, Type 2 - mortality
- Diabetic Nephropathies - blood
- Diabetic Nephropathies - etiology
- Diabetic Nephropathies - mortality
- Diabetic Nephropathies - therapy
- Double-Blind Method -
- Dyslipidemias - blood
- Dyslipidemias - complications
- Dyslipidemias - drug therapy
- Dyslipidemias - mortality
- Female -
- Germany -
- Heptanoic Acids - therapeutic use
- Humans -
- Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
- Logistic Models -
- Male -
- Middle Aged -
- Proportional Hazards Models -
- Prospective Studies -
- Pyrroles - therapeutic use
- Renal Dialysis - adverse effects
- Renal Dialysis - mortality
- Risk Assessment -
- Risk Factors -
- Time Factors -
- Treatment Outcome -